Market Overview - On September 24, the medical device sector rose by 0.1% compared to the previous trading day, with Hualan Co., Ltd. leading the gains [1] - The Shanghai Composite Index closed at 3853.64, up 0.83%, while the Shenzhen Component Index closed at 13356.14, up 1.8% [1] Top Performers - Hualan Co., Ltd. (301093) closed at 44.74, up 10.20% with a trading volume of 120,900 shares and a transaction value of 526 million yuan [1] - Huitai Medical (688617) closed at 321.65, up 6.86% with a trading volume of 21,200 shares [1] - Jinhao Medical (872925) closed at 31.15, up 6.68% with a trading volume of 17,400 shares [1] Other Notable Stocks - Dongxing Medical (301290) closed at 27.96, up 5.35% with a trading volume of 34,600 shares [1] - Dabo Medical (002901) closed at 55.06, up 5.02% with a trading volume of 42,100 shares [1] - Maike Aodi (300341) closed at 18.79, up 4.97% with a trading volume of 373,300 shares [1] Fund Flow Analysis - The medical device sector experienced a net outflow of 12.47 million yuan from institutional investors, while retail investors saw a net inflow of 24.3 million yuan [2] - The overall fund flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors increased their positions [2] Individual Stock Fund Flow - Maike Aodi (300341) had a net inflow of 94.47 million yuan from institutional investors, but a net outflow of 85.20 million yuan from retail investors [3] - Huo Jing Biological (688068) saw a net inflow of 58.76 million yuan from institutional investors, with retail investors also withdrawing funds [3] - Dabo Medical (002901) had a net inflow of 33.73 million yuan from institutional investors, while retail investors experienced a net outflow [3]

Group 1 - The core viewpoint of the news is that Hualan Co., Ltd. has seen a 5% increase in stock price, reaching 42.63 yuan per share, with a total market capitalization of 7 billion yuan [1] - Hualan Co., Ltd. specializes in the research, production, and sales of packaging materials for injectable drugs, with its main revenue sources being film-coated rubber stoppers (49.07%) and conventional rubber stoppers (48.50%) [1] - The company was established on June 4, 1992, and went public on November 1, 2021 [1] Group 2 - According to data, Dachen Fund has a significant holding in Hualan Co., Ltd., with its Dachen Growth Mixed Fund holding 620,000 shares, accounting for 3.29% of the fund's net value [2] - The Dachen Growth Mixed Fund has achieved a year-to-date return of 23.45% and a one-year return of 46.55% [2] - The fund manager, Zou Jian, has been in position for 4 years and 243 days, with the fund's total asset size currently at 1.086 billion yuan [2]

Group 1 - The stock price of Hualan Biological Engineering reached a historical high, increasing by 4.85% to 42.57 yuan, with a trading volume of 2.7837 million shares and a transaction value of 115 million yuan, resulting in a turnover rate of 1.77% [2] - The latest total market capitalization of Hualan Biological is 6.99 billion yuan, with a circulating market capitalization of 6.681 billion yuan [2] - The pharmaceutical and biotechnology industry, to which Hualan belongs, has an overall increase of 0.48%, with 377 stocks rising, including notable gainers such as Sunflower, Ganli Pharmaceutical, and Xinlitai, which rose by 15.13%, 8.97%, and 6.83% respectively [2] Group 2 - The latest margin trading data shows that Hualan's margin balance is 490 million yuan, with a financing balance of 490 million yuan, which has increased by 42.599 million yuan over the past 10 days, reflecting a growth of 9.52% [2] - According to the company's semi-annual report, Hualan achieved an operating income of 309 million yuan in the first half of the year, representing a year-on-year growth of 8.82%, and a net profit of 43.7321 million yuan, which is an increase of 18.27% year-on-year, with basic earnings per share of 0.2700 yuan and a weighted average return on equity of 1.93% [2]

Group 1 - The core point of the article is that Hualan Co., Ltd. has launched an employee stock ownership plan for 2025, aiming to raise a total of no more than 56.85 million yuan, involving no more than 2.92 million shares, which accounts for approximately 1.78% of the company's total share capital [1] - The plan includes participation from no more than 260 senior management and key personnel, with profit growth targets set for the years 2025, 2026, and 2027, requiring net profit increases of 50%, 105%, and 155% respectively compared to 2024 [1] - The company reported a revenue of 309 million yuan in the first half of 2025, representing a year-on-year growth of 8.82%, and a net profit attributable to shareholders of 43.73 million yuan, up 18.27% year-on-year [1] Group 2 - The increase in net profit is primarily attributed to a rise in revenue, which led to an increase in gross profit by 9.73 million yuan, alongside a reduction in sales expenses by 3.20 million yuan due to optimized sales policies [1] - The company has been actively expanding its market, with revenue from its core product, film-coated rubber stoppers, increasing by 9.28%, and the gross margin improving by 2.16 percentage points to 53.62% [1] - Revenue from conventional rubber stoppers grew by 7.94%, although the gross margin decreased by 1.64 percentage points to 25.64% [1]

Core Viewpoint - Hualan Co., Ltd. announced an employee stock ownership plan for 2025, aiming to raise a total of 56.85 million yuan, including reserved shares [1] Summary by Sections Employee Stock Ownership Plan - The employee stock ownership plan has a maximum fundraising target of 56.85 million yuan, with shares being the unit of subscription, requiring employees to subscribe in whole numbers [1] - The reward fund is capped at 24.85 million yuan, and the incentive fund will be accounted for as an expense based on the accrual basis [1] - The shares for this plan will be sourced from the company's repurchased A-share common stock held in a dedicated repurchase account [1] Share Distribution - The plan has been approved by the company's shareholders, and the shares in the repurchase account will be transferred to the employee stock ownership plan through legally permitted methods such as non-trading transfers [1] - The total number of shares held by the employee stock ownership plan will not exceed 2.92 million shares, which represents approximately 1.78% of the company's current total share capital [1]

江苏华兰药用新材料股份有限公司 2025 年员工持股计划 （草案） 证券简称：华兰股份 证券代码：301093 江苏华兰药用新材料股份有限公司 2025 年员工持股计划 （草案） 二〇二五年九月 1 江苏华兰药用新材料股份有限公司 2025 年员工持股计划 （草案） 公司声明 本公司及董事会全体成员保证本员工持股计划不存在任何虚假记载、误导 性陈述或重大遗漏，并对其内容真实性、准确性、完整性承担个别和连带的 法律责任。 2 江苏华兰药用新材料股份有限公司 2025 年员工持股计划 （草案） 风险提示 本部分内容中的词语简称与"释义"部分保持一致。 一、江苏华兰药用新材料股份有限公司 2025 年员工持股计划需经公司股 东会审议通过后方可实施，本员工持股计划能否获得公司股东会批准，存在不 确定性。 二、本员工持股计划遵循依法合规、自愿参与、风险自担原则，若员工认 购资金不足，本员工持股计划存在低于预计规模的风险。 三、有关本员工持股计划的具体资金来源、实施方案等属初步结果，能否 完成实施，存在不确定性。 四、本员工持股计划中有关公司业绩考核指标的描述不代表公司的业绩预 测，亦不构成业绩承诺。 五、公司后续将根据 ...

江苏华兰药用新材料股份有限公司 董事会关于 2025 年员工持股计划（草案）合规性的说明 江苏华兰药用新材料股份有限公司（以下简称"公司"）根据《中华人民共 和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称 "《证券法》"）以及《关于上市公司实施员工持股计划试点的指导意见》（以下 简称"《指导意见》"）、《深圳证券交易所上市公司自律监管指引第 2 号——创业 板上市公司规范运作》（以下简称"《创业板上市公司规范运作》"）等有关法律 法规、规范性文件及《公司章程》的有关规定，制定了《2025 年员工持股计划 （草案）》（以下简称"本次员工持股计划"），董事会现就本次员工持股计划符合 《指导意见》等相关规定说明如下： 一、公司不存在《指导意见》《创业板上市公司规范运作》等法律、法规规 定的禁止实施员工持股计划的情形，公司具备实施员工持股计划的主体资格。 二、本次员工持股计划内容符合《指导意见》《创业板上市公司规范运作》 等有关法律、法规及规范性文件的规定，公司推出本次员工持股计划前，已通过 职工代表大会充分征询了员工意见。 三、本次员工持股计划关联董事已根据相关规定回避表决，公司审议本次 ...

证券简称：华兰股份 证券代码：301093 江苏华兰药用新材料股份有限公司 2025 年员工持股计划 （草案）摘要 二、本员工持股计划遵循依法合规、自愿参与、风险自担原则，若员工认 购资金不足，本员工持股计划存在低于预计规模的风险。 二〇二五年九月 1 公司声明 本公司及董事会全体成员保证本员工持股计划不存在任何虚假记载、误导 性陈述或重大遗漏，并对其内容真实性、准确性、完整性承担个别和连带的 法律责任。 2 风险提示 本部分内容中的词语简称与"释义"部分保持一致。 一、江苏华兰药用新材料股份有限公司 2025 年员工持股计划需经公司股 东会审议通过后方可实施，本员工持股计划能否获得公司股东会批准，存在不 确定性。 三、有关本员工持股计划的具体资金来源、实施方案等属初步结果，能否 完成实施，存在不确定性。 四、本员工持股计划中有关公司业绩考核指标的描述不代表公司的业绩预 测，亦不构成业绩承诺。 五、公司后续将根据规定披露相关进展情况，敬请广大投资者谨慎决策， 注意投资风险。 3 特别提示 本部分内容中的词语简称与"释义"部分保持一致。 一、《江苏华兰药用新材料股份有限公司 2025 年员工持股计划（草案）》 ...

证券代码：301093 证券简称：华兰股份 公告编号：2025-096 江苏华兰药用新材料股份有限公司 （四） 会议召开的日期、时间 1、 现场会议召开时间：2025 年 10 月 9 日（星期四）下午 14:30。 2、 网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时间 为：2025 年 10 月 9 日上午 9:15 至 9:25，9:30 至 11:30，下午 13:00 至 15:00；通 过互联网投票系统进行网络投票的具体时间为：2025 年 10 月 9 日上午 9:15 至下 午 15:00 内的任意时间。 关于召开 2025 年第五次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 江苏华兰药用新材料股份有限公司（以下简称"公司"或"华兰股份"）第 六届董事会第五次会议，决定于 2025 年 10 月 9 日（星期四）下午 14：30 在公 司会议室以现场投票与网络投票相结合的方式召开 2025 年第五次临时股东会。 现将本次会议有关事项通知如下： 一、 召开会议的基本情况 （一） 股东会届次：2025 年第五次临 ...

江苏华兰药用新材料股份有限公司 董事会薪酬与考核委员会关于公司 2025 年员工持股计划 特此说明。 江苏华兰药用新材料股份有限公司 相关事项的核查意见 江苏华兰药用新材料股份有限公司（以下简称"公司"）董事会薪酬与考核 委员会根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共 和国证券法》（以下简称"《证券法》"）以及《关于上市公司实施员工持股计划 试点的指导意见》（以下简称"《指导意见》"）、《深圳证券交易所上市公司自律 监管指引第 2 号——创业板上市公司规范运作》（以下简称"《创业板上市公司 规范运作》"）等有关法律法规、规范性文件及《公司章程》的有关规定，对公司 2025 年员工持股计划（以下简称"本次员工持股计划"）相关事项进行了认真核 查，现发表意见如下： 五、公司实施本次员工持股计划有利于建立公司优秀人才与股东成果共享、 风险共担机制；有利于优化薪酬结构，合理配置激励资源，吸引、留住和激励优 秀人才，促进公司长期稳定发展和股东价值提升。 综上所述，公司董事会薪酬与考核委员会同意公司实行 2025 年员工持股计 划。 一、公司不存在《指导意见》《创业板上市公司规范运作》等法律法 ...